Skip to main content
Premium Trial:

Request an Annual Quote

Baylor College of Medicine, Miraca Form Genetic Testing Joint Venture

NEW YORK (GenomeWeb) – Baylor College of Medicine and Miraca Holdings today announced a joint venture that links a genetics research program with a diagnostics firm.

The joint venture called Baylor Miraca Genetics Laboratories will be headquartered in Houston and built on Baylor's existing Medical Genetics Laboratories, which conducts clinical laboratory genetic testing. Initially, the joint venture will employ about 225 people, Baylor said in a statement.

Baylor President and CEO Paul Klotman said that the partnership is anticipated to lead to "tremendous growth of our clinical genetics testing program, while ensuring the quality of diagnostics to patients and healthcare providers on an international level."

Baylor has provided diagnostic services for more than 35 years and is home to three US-based large-scale genome sequencing centers funded by the National Institutes of Health. Regardless, academic medical centers and teaching hospitals in the Houston area have fallen behind those in other regions in bringing their innovations to market, Klotman said. The partnership with Miraca could change that, he added.

Miraca is based in Tokyo and provides in vitro diagnostics, clinical laboratory testing, and other healthcare services and products through its subsidiaries, such as Fujirebio and SRL. It also owns Miraca Life Sciences, based in Irving, Texas, which it said is the largest independent anatomic pathology business in the US.

The partners said that Baylor will continue to independently carry out its genetic diagnostic research program, and the joint venture "is expected to fully support the academic mission of the college's department of molecular and human genetics."

Baylor's faculty involved in clinical diagnostics will remain faculty members and employees of the college. Its educational training programs in genetics and genome sequencing will continue operating through a formal academic affiliation with the joint venture.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.